25-hydroxyvitamin d levels and risk of ischemic heart disease, myocardial infarction, and early death: population-based study and meta-analyses of 18 and 17 studies
Brøndum-Jacobsen P, Benn M, Jensen GB, Nordestgaard BG
Arteriosclerosis, thrombosis, and vascular biology · 187 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2012-08-31 · Arterioscler Thromb Vasc Biol · vol. 32 · número 11 · págs. 2794–2802
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 240 citas · más que el 100% de estudios similares · 16.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 41 trabajos
- Acceso
- De pago
- Áreas de investigación
- Vitamin D Research Studies · Nutritional Studies and Diet · Cardiovascular Health and Risk Factors
- Palabras clave
- 25-hydroxyvitamin D, vitamin D deficiency, ischemic heart disease, myocardial infarction, early mortality, cardiovascular risk, plasma vitamin D levels, seasonal variation
- MeSH
- humans, myocardial ischemia, myocardial infarction, vitamin d deficiency, vitamin d, prognosis, incidence, multivariate analysis, proportional hazards models, risk assessment, risk factors, follow-up studies, prospective studies, time factors, aged, middle aged, denmark, female, male, kaplan-meier estimate, biomarkers
4 autores
- Peter Brøndum-Jacobsen🇩🇰University of Copenhagen; Herlev Hospital; Bispebjerg Hospital; Copenhagen University Hospital
- Marianne Benn🇩🇰University of Copenhagen; Herlev Hospital; Bispebjerg Hospital; Copenhagen University Hospital
- Gorm Boje Jensen🇩🇰University of Copenhagen; Herlev Hospital; Bispebjerg Hospital; Copenhagen University Hospital
- Børge Grønne Nordestgaard🇩🇰University of Copenhagen; Herlev Hospital; Bispebjerg Hospital; Copenhagen University Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
We tested the hypothesis that reduced plasma 25-hydroxyvitamin D associates with increased risk of ischemic heart disease, myocardial infarction, and early death.
Methods and results
We measured baseline plasma 25-hydroxyvitamin D in 10 170 women and men from the Danish general population without vitamin D-fortified food. During 29 years of follow-up, 3100 persons developed ischemic heart disease, 1625 myocardial infarction, and 6747 died. Decreasing plasma 25-hydroxyvitamin D levels were associated with increasing risk of ischemic heart disease, myocardial infarction, and early death as a function of seasonally adjusted percentile categories (P for trend, 2×10(-4)-3×10(-53)). Comparing individuals with plasma 25-hydroxyvitamin D levels at the 1st to 4th percentile with individuals with levels at the 50th to 100th percentile, the multivariable adjusted risk was increased by 40% (95% CI, 14%-72%) for ischemic heart disease, by 64% (25%-114%) for myocardial infarction, by 57% (38%-78%) for early death, and by 81% (40%-135%) for fatal ischemic heart disease/myocardial infarction. In the meta-analyses of 18 and 17 studies, risk of ischemic heart disease and early death were increased by 39% (25%-54%) and 46% (31%-64%) for lowest versus highest quartile of 25-hydroxyvitamin D level.
Conclusions
We observed increasing risk of ischemic heart disease, myocardial infarction, and early death with decreasing plasma 25-hydroxyvitamin D levels. These findings were substantiated in meta-analyses.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.